Free Trial
Final Hours! MarketBeat All Access at $149 Until 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

BTIG Research's Rating of Kymera Therapeutics on 10/29/2026

On October 29, 2026, BTIG Research updated its outlook on Kymera Therapeutics (NASDAQ:KYMR) with the action "Boost Price Target", setting a price target of $139.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
10/29/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Lower Price Target
10/29/2026
Crocs, Inc. stock logo
CROX
Crocs
Reiterated Rating
10/29/2026
eBay Inc. stock logo
EBAY
eBay
Initiated Coverage
10/29/2026
Boot Barn Holdings, Inc. stock logo
BOOT
Boot Barn
Lower Price Target
10/29/2026
DraftKings Inc. stock logo
DKNG
DraftKings
Boost Price Target
10/29/2026
American Electric Power Company, Inc. stock logo
AEP
American Electric Power
Reiterated Rating
More Ratings From BTIG Research